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Abstract: The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE 
study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 μg 
twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with 
moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the 
Genuair™/Pressair® dry powder inhaler for 8 weeks. From Weeks 5 to 8, all patients partici-
pated in behavioral intervention (BI; daily messages providing step goals). The primary end 
point was trough functional residual capacity (FRC) at Week 4. Exercise endurance time and 
physical activity were assessed at Week 4 (pharmacotherapy only) and at Week 8 (8 weeks 
of pharmacotherapy plus 4 weeks of BI). Other end points included post-dose FRC, residual 
volume, and inspiratory capacity (IC) at rest and during exercise. After 4 weeks, trough FRC 
improved with AB/FF versus placebo but did not reach significance (125 mL; P=0.0690). 
However, post-dose FRC, residual volume, and IC at rest improved significantly with AB/FF at 
Week 4 versus placebo (all P,0.0001). AB/FF significantly improved exercise endurance time 
and IC at isotime versus placebo at Week 4 (P,0.01 and P,0.0001, respectively) and Week 8 
(P,0.05 and P,0.0001, respectively). AB/FF achieved higher step counts (P,0.01) with 
fewer inactive patients (P,0.0001) at Week 4 versus placebo. Following BI, AB/FF maintained 
improvements in physical activity at Week 8 and nonsignificant improvements were observed 
with placebo. AB/FF 400/12 μg demonstrated improvements in lung hyperinflation, exercise 
capacity, and physical activity versus placebo that were maintained following the addition of 
BI. A 4-week period of BI might be too short to augment the improvements of physical activity 
observed with AB/FF.
Keywords: COPD, hyperinflation, aclidinium, formoterol, exercise capacity, physical activity
Plain language summary
Why was the study done? Patients with COPD often suffer from breathlessness that affects 
their ability to exercise and go about their daily activities. Being less physically active can lead 
to an increase in COPD symptoms and a worsening of the patient’s COPD, which in turn can 
result in further reductions in physical activity. Therefore, a key part of COPD management is 
helping patients to increase their activity levels and to stay active.
What did the researchers do and find? The researchers looked at the effect of aclidinium/
formoterol, a combination of two different inhaled COPD treatments, on lung function and 
physical activity. Patients taking aclidinium/formoterol for 4 weeks had better lung function 
than patients taking placebo. Patients taking aclidinium/formoterol could also exercise for 
longer and increased their daily physical activity by around 730 steps more per day than patients 
taking placebo. Additionally, when these patients used a mobile phone application to encourage 
increased activity for a further 4 weeks, improvements in physical activity were maintained.
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What do these results mean? These results suggest that 
aclidinium/formoterol can improve lung function and physical 
activity in patients with COPD, particularly when used together 
with a mobile phone application to encourage and support 
activity.
Introduction
COPD is a common, preventable, and treatable disease, 
characterized by persistent respiratory symptoms and airflow 
limitation.1 Dyspnea on exertion is the primary symptom 
limiting exercise capacity in patients with COPD, which in 
turn leads to reduced physical activity in their daily life.2 
Consequently, as activity-related dyspnea increases, physical 
activity reduces significantly, not only in patients with severe 
COPD but also in patients with mild-to-moderate disease.3–5 
As reduced physical activity in patients with COPD is 
independently linked to reduced quality of life,6 increased 
hospitalizations,7 physical deconditioning,3,8 and mortality,9 
an improvement in physical activity has been identified as 
potentially disease-modifying, with better long-term out-
comes in this debilitating disease.2,10
Lung hyperinflation is thought to present a mechanical 
link between reduced physical activity and the airflow limi-
tation in patients with COPD.11,12 In these patients, physical 
activity reflects the amount of activity performed in a real-life 
setting (eg, number of steps taken per day), while exercise 
capacity is the amount of exercise that patients are capable 
of doing (ie, functional capacity measured by walking or 
cycling tests).2,13 A number of pharmacological therapies 
that improve airflow and reduce lung hyperinflation have 
also been shown to provide improvements in exercise capac-
ity in COPD.11,14–18 However, the effects of bronchodilator 
treatment on physical activity are less clear.17–21
Physical inactivity in patients with COPD is not only related 
to functional limitations but also results from a complex health 
behavior, which can be changed using behavioral intervention 
(BI).22 Therefore, as well as instigating bronchodilator therapy, 
consideration should be given to implementing BI, so that 
patients may be able to make use of the improved exercise 
tolerance – gained from pharmacotherapy – in daily life.
ACTIVATE (NCT02424344) was a Phase IV, multi-
center, 8-week, multiple-dose, randomized, double-blind, 
placebo-controlled, parallel-group study of aclidinium 
bromide/formoterol fumarate (AB/FF) 400/12 μg twice daily 
(b.i.d.). Study objectives were the effect of AB/FF versus pla-
cebo on lung hyperinflation (prior to BI), exercise endurance 
time (EET), and physical activity with/without BI in patients 
with moderate-to-severe COPD.
Materials and methods
study subjects
The ACTIVATE study was conducted between April 2015 
and July 2016 across 26 sites in four countries (Canada, 
Germany, Hungary, and Spain). Clinical trial registration 
number: NCT02424344 (ClinicalTrials.gov).
Patients were aged $40 years, current or former ciga-
rette smokers with a clinical diagnosis of moderate/severe 
COPD, with a functional residual capacity (FRC) $120% 
of predicted value, a post-bronchodilator forced expiratory 
volume in 1 s (FEV
1
) $40% and ,80% of the predicted 
value, an FEV
1
/forced vital capacity (FVC) ,70%, and a 
modified Medical Research Council (mMRC) dyspnea scale 
score of $2. Details on inclusion and exclusion criteria are 
described in the Supplementary material.
Prohibited medication throughout the whole study period 
(including screening, run-in, and the 8-week treatment period) 
included any bronchodilator treatment (with the exception of 
salbutamol used as rescue medication), methylxanthines, and 
phosphodiesterase type 4 inhibitors. Patients were allowed 
to continue inhaled corticosteroid therapy, oral or parenteral 
corticosteroids at a dose equivalent to 10 mg of prednisone per 
day or 20 mg every other day, and oxygen therapy ,15 h per 
day if the administration had been stable for $4 weeks.
All patients provided written, informed consent prior to 
conducting any study-specific procedures. This study was 
approved by local ethics committees (Table S1) and per-
formed in accordance with the Declaration of Helsinki and 
Good Clinical Practice Guidelines.
study design
In this Phase IV ACTIVATE study, patients were random-
ized (1:1) to receive AB/FF 400/12 μg or placebo b.i.d. 
via a multidose dry powder inhaler (Genuair™/Pressair® 
[Registered trademark of AstraZeneca group of companies; 
for use within the USA as Pressair and as Genuair within all 
other licensed territories]). There was an 11–17-day run-in 
and screening period and an 8-week treatment period, with a 
follow-up phone call 2 weeks after the final treatment. During 
the first 4 weeks of the study, patients received pharmaco-
therapy alone (AB/FF or placebo) and, during the second 
4 weeks, BI was added to both treatment arms (Figure 1).
end points and measurements
The primary efficacy end point was change from baseline 
in trough FRC after 4 weeks of treatment. The secondary 
efficacy end points were change from baseline in EET during 
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constant work rate cycle ergometry to symptom limitation at 
75% of peak work rate (W
max
) and the percentage of inactive 
patients (,6,000 steps per day) after 8 weeks of treatment. 
Additional efficacy end points included the percentage 
of inactive patients (,6,000 steps per day) after 4 weeks 
of treatment; change from baseline in physical activity 
parameters after 4 and 8 weeks of treatment; inspiratory 
capacity (IC) during constant work rate cycle ergometry; 
change from baseline in Daily PROactive Physical Activity in 
COPD (D-PPAC) questionnaire scores (total, amount, and 
difficulty) after 4 and 8 weeks of treatment; and pulmonary 
function variables after 4 weeks of treatment (pre-dose FEV
1
 
and FVC, post-dose FRC, pre- and post-dose specific airway 
conductance [sGaw], and residual volume [RV]).
Lung function was assessed using body plethysmog-
raphy (FRC, RV, and sGaw) and spirometry (FVC and 
FEV
1
) before exercise, at baseline, and at Week 4, as 
previously described,18 and in accordance with current 
recommendations.23–25 Plethysmography was assessed using 
MasterScreen Body Plethysmograph (eResearchTechnology 
[ERT] Inc., Philadelphia, USA, formerly Jaeger/Viasys/
Carefusion), calibrated daily and with monthly, healthy 
subject quality control tests for consistency. If different 
plethysmography equipment was used, it was assessed for 
technical and setup issues prior to the start of the study.
EET was measured using cycle ergometry at constant work 
rate at 75% W
max
 at baseline and at 3 h post-dose at Weeks 4 
and 8, as previously described.18 Three minutes of rest was 
followed by 3 minutes of unloaded cycling, before patients 
were encouraged to maintain a 50–70 revolutions per minute 
pedal rate at 75% W
max
 until symptom limitation.18 IC was 
measured using a spirometer at rest, during, and at the end 
of EET assessment. Cycle ergometry was assessed using 
MasterScreen CPX Ergometry with Ergoline Ergoselect 
Cycling equipment (ERT Inc., Philadelphia, PA, USA). 
The spirometry system was calibrated daily and quality 
control tests were performed in all sites. If different cycle 
ergometry equipment was used, it was assessed for techni-
cal and setup issues prior to the start of the study.
Physical activity levels were measured at baseline, at 
Week 4, and at Week 8 using an activity monitor (DynaPort 
MoveMonitor, McRoberts B.V., the Hague, the Netherlands)26 
for a period of 1 week each, as previously described.22,27 
Patients wore the accelerometer for 24 h a day, with the excep-
tion of time spent on personal hygiene.4 Days were considered 
valid for the physical activity dataset if .8 h of wearing time 
was recorded on at least 3 days within 1 week (not necessarily 
consecutive). The average number of steps taken per day, the 
time in moderate-intensity activities per day (.3 metabolic 
equivalents as estimated by accelerometer), and the activity-
related energy expenditure were recorded.18
Physical activity experience was assessed using the 
D-PPAC questionnaire, a daily recall, electronic, patient-
reported outcome (PRO) tool developed by the Innovative 
Medicines Initiative PROactive project. The D-PPAC was 
filled out by patients every evening for a week at baseline, 
at Week 4, and at Week 8. This seven-item PRO measure 
consists of two physical activity experience domains: amount 
Figure 1 study design.
Abbreviations: BI, behavioral intervention; b.i.d., twice daily; V, visit; W, week.
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and difficulty.27 The amount domain consists of two PRO 
items plus two activity monitor outputs (steps per day and 
vector magnitude units per minute); the difficulty domain 
consists of five PRO items. The total score was calculated 
as the average of both domain scores. Each domain and 
the total were scored from 0 to 100, where higher numbers 
indicated a better score. A minimum of 3 days of simultane-
ous monitoring and questionnaire items were needed for a 
valid assessment.
BI was facilitated using a smartphone application con-
nected to a step counter (Linkcare®, Barcelona, Spain), 
received at Visit 4 of the study, using the goal-setting prin-
ciples previously described.22 A day was classified as valid if 
the patient took .70 steps per day. Individualized step goals 
were set based on the median value of the four most active 
days in the previous week. If the patient reached their goal, 
the goal for the following week was either kept the same or 
increased by 500 steps per day (depending on the patient’s 
preference). If the patient did not reach their goal, the new 
goal was either unchanged or set to 500 steps more than the 
median number of steps per day achieved in the previous 
week (whichever was lowest). Patients who took ,70 steps 
a day on .3 days kept the same goal as in the previous week. 
Patients were reminded of their goal in the morning, were 
able to check their progress throughout the day, and received 
feedback messages in the evening, as well as receiving 
motivational and educational messages. Patients received 
summary feedback at the end of the week.
Treatment-emergent adverse events (TEAEs; including 
COPD exacerbations), concomitant medication use, and 
rescue medication use were recorded throughout the study.
statistical analysis
The sample size was calculated to provide $80% power to 
detect a significant difference of -0.200 L with a common 
standard deviation (SD) of 0.545 L in change from baseline 
in trough FRC at Week 4 of treatment, and 100 s with a 
common SD of 260 s in change from baseline in EET dur-
ing constant work rate cycle ergometry to symptom limita-
tion at 75% W
max
 at Week 8 of treatment, when comparing 
AB/FF 400/12 μg with placebo, and based on a two-sided 
test at a significance level of 0.05. A hierarchical multiplic-
ity approach was used with the following order: change 
from baseline in FRC for AB/FF 400/12 μg compared with 
placebo (primary end point); change from baseline in EET 
for AB/FF 400/12 μg compared with placebo; and percent-
age of inactive patients (,6,000 steps per day) for AB/FF 
400/12 μg compared with placebo. End points were tested 
hierarchically, with subsequent end points tested providing 
the previous end point achieved a 5% significance level. The 
primary end point was analyzed using analysis of covari-
ance (ANCOVA) models, and the secondary and additional 
end points were analyzed using mixed models for repeated 
measures. Detailed statistical methods are provided in the 
Supplementary material.
The safety population (used for adverse event [AE] 
analyses) and the intent-to-treat (ITT) population (used 
for efficacy analyses) were both defined as all randomized 
patients who took at least one dose of study medication.
Results
study population
Of the 335 patients screened, 267 were randomized (AB/FF, 
n=134; placebo, n=133) and 250 completed the study (AB/FF, 
n=127; placebo, n=123) (Figure 2). Patient demographics and 
characteristics were similar between groups (Table 1).
Efficacy
lung function
Patients receiving AB/FF demonstrated a greater reduction 
in adjusted mean change from baseline versus placebo in 
trough FRC at Week 4, but this did not reach statistical 
significance (0.125 L; P=0.069; Figure 3). As this primary 
end point did not achieve statistical significance, all P-values 
for secondary and additional end points are nominal and no 
formal statistical inference can be drawn.
Post-hoc analysis of change from baseline versus 
placebo in trough FRC, based on a nonparametric Wilcox-
on–Mann–Whitney test, showed a statistically significant 
difference between AB/FF and placebo (P=0.0034). Esti-
mated asymptotic shift (Hodges–Lehmann) was -0.170 L 
(95% CI: -0.300 L, -0.060 L). In addition, the post-hoc 
outlier and influential data analysis identified four outlying 
patients: two in the AB/FF treatment group and two in the 
placebo group. Once these patients were excluded from the 
ITT ANCOVA analysis, a statistically significant reduction 
of 0.196 L (P=0.0010) between AB/FF and placebo was 
demonstrated.
Lung hyperinflation and other pulmonary function mea-
surements are reported in Table 2. Of note, post-dose lung 
hyperinflation measurements showed significant improve-
ments in change from baseline in FRC, RV, IC, and sGaw at 
Week 4 with AB/FF, compared with placebo (0.366 L, 0.465 L, 
0.293 L, and 0.341 s-1 kPa-1 respectively; all P,0.0001; 
Table 2). Furthermore, a significant improvement in adjusted 
mean change from baseline in pre-dose (trough) FEV
1
 was 
found for AB/FF compared with placebo at Week 4 (0.209 L; 
P,0.0001; Table 2).
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exercise capacity
Compared with placebo, patients treated with AB/FF had 
greater improvements from baseline in exercise capacity 
during constant cycle ergometry at 75% W
max
, as demon-
strated by a longer adjusted mean change from baseline in 
EET at both Week 4 (58.9 s; P=0.0089) and Week 8 (55.2 s; 
P=0.0292; Figure 4A). Additionally, improvements in IC 
during exercise were also observed at both Weeks 4 and 8, 
with a treatment difference in IC at isotime of 0.246 L and 
0.226 L, and at the end of exercise of 0.218 L and 0.194 L 
(all P,0.0001) (Figure 4B).
Physical activity
Mean daily wearing time for activity monitors was around 
23 h throughout the study (23 h 27 min at baseline, 23 h 
18 min at Week 4, and 22 h 57 min at Week 8). After 4 weeks 
of treatment, the percentage of inactive patients on AB/FF 
was significantly lower compared with placebo (odds ratio 
[OR], 0.27; P,0.0001; Figure 5A). Patients receiving AB/FF 
showed significant improvements in the number of steps per 
day (621; standard error [SE], 167) compared with a decrease 
of 110 (SE, 167) steps per day in placebo (treatment difference 
of 731 steps per day; P=0.0016; Figure 5B). Significant treat-
ment differences were also observed for daily duration of at 
least moderate-intensity activities and activity-related energy 
expenditure (Figures S1 and S2). During the last 4 weeks 
of the study (from Week 5 to Week 8), BI maintained the 
improvements achieved in the number of steps per day after 
4 weeks of AB/FF treatment (increase of 32 steps per day from 
Week 4 to Week 8). In contrast, patients receiving placebo had 
an improvement of 252 steps per day from Week 4 to Week 8, 
corresponding to a numerical difference of 510 steps per day 
(P=0.1588; Figure 5B) for AB/FF compared with placebo, and 
a numerical difference in the percentage of inactive patients in 
favor of the AB/FF group (OR, 0.44; P=0.1134; Figure 5A).
The D-PPAC questionnaire total score, amount, and 
difficulty domains improved significantly in the AB/FF group 
versus placebo at Week 4 (P,0.03; Figure 6). At Week 8, 
AB/FF maintained the improvements seen after 4 weeks; 
however, the differences versus placebo were not statistically 
significant (Figure 6).
safety
The number of TEAEs was comparable between AB/FF and 
placebo (42.5% and 45.1%, respectively), with low numbers 
of serious AEs and AEs leading to discontinuation in both 
treatment groups (AB/FF: 1.5% and 3.0%; placebo: 2.3% 
and 4.5%, respectively). Nasopharyngitis (AB/FF, 10.4%; 
placebo, 9.8%) and headache (AB/FF, 3.0%; placebo, 9.0%) 
were the only events reported by .5% of patients.
Discussion
In the ACTIVATE study, treatment with AB/FF 400/12 μg 
significantly improved lung hyperinflation in patients with 
Figure 2 Patient flow.
Abbreviations: AB, aclidinium bromide; AE, adverse event; FF, formoterol fumarate.
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in steps per day (~10% increase) appear more pronounced 
than those seen with aclidinium alone (~6% increase).18 
Additionally, the improvement in EET of ~1 minute with 
AB/FF is similar to previous studies evaluating the effect of 
dual bronchodilation on exercise capacity28,29 and is in the 
range considered clinically significant.30,31
The maximum treatment difference in physical activity 
between AB/FF and placebo was observed during the first 
4 weeks of treatment, prior to BI, with no substantial further 
increase of physical activity in patients on active treat-
ment during BI. In patients receiving placebo, BI led to an 
increase in physical activity, although this was nonsignificant. 
Table 1 Baseline demographics and clinical characteristics (ITT 
population)
Placebo 
(n=133)
AB/FF 
400/12 μg 
(n=134)
Total 
(n=267)
Age, mean years (SD) 62.1 (7.7) 62.6 (7.9) 62.3 (7.8)
Male, % 59.4 60.5 59.9
Current smoker, % 62.4 63.4 62.9
Smoking history, mean 
pack-years (sD)
46.4 (21.6) 48.4 (24.0) 47.4 (22.8)
COPD severity, %
Moderate 82.0 76.7 79.3
severe 18.0 23.3 20.7
Post-bronchodilator FeV1% 
predicted, mean (SD)
61.0 (10.7) 60.3 (10.7) 60.7 (10.7)
FRC % predicted, mean (SD) 148.0 (26.2) 151.4 (27.7) 149.7 (27.0)
mMRC scale, %
grade 2 91.7 91.0 91.4
grade 3 8.3 9.0 8.6
Prior medication
LAMA, n (%) 23 (17.3) 24 (17.9) 47 (17.6)
LABA, n (%) 11 (8.3) 16 (11.9) 27 (10.1)
ICS, n (%) 8 (6.0) 2 (1.5) 10 (3.8)
LAMA/LABA, n (%) 40 (30.1) 34 (25.4) 74 (27.7)
LABA/ICS, n (%) 14 (10.5) 17 (12.7) 31 (11.6)
LAMA/ICS, n (%) 1 (0.8) 2 (1.5) 3 (1.1)
LAMA/LABA/ICS, n (%) 5 (3.8) 11 (8.2) 16 (6.0)
number of exacerbations in 
previous year, mean (SD)
0.4 (1.0) 0.3 (0.5) 0.3 (0.8)
Mean endurance time, s (SD) 456.9 
(181.7)
455.8 
(184.9)
456.3 
(183.0)
Inactive patients,a % 48.1 54.6 51.4
Mean number of steps per 
day (sD)
6,186.9 
(3,066.5)
6,368.4 
(3,398.6)
6,278.0 
(3,232.5)
D-PPaC
Total score, mean (SD) 62.5 (9.7) 62.5 (10.1) 62.5 (9.9)
Difficulty domain, mean (SD) 70.8 (13.9) 69.6 (13.6) 70.1 (13.7)
Amount domain, mean (SD) 53.7 (14.2) 54.5 (13.0) 54.1 (13.5)
Note: aInactive patients classified as logging ,6,000 steps per day.
Abbreviations: AB, aclidinium bromide; D-PPAC, Daily PROactive Physical Activity 
in COPD; FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; FRC, 
functional residual capacity; ICS, inhaled corticosteroids; ITT, intent-to-treat; LABA, 
long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified 
Medical Research Council; SD, standard deviation.
Figure 3 Change from baseline in trough FrC at Week 4 (ITT population).
Note: Data are LSMs (95% CI).
Abbreviations: AB, aclidinium bromide; CI, confidence interval; FF, formoterol 
fumarate; FRC, functional residual capacity; ITT, intent-to-treat; LSM, least 
squares mean.
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Table 2 lung function at Week 4 (ITT population)
Placebo 
(n=133)
AB/FF 
400/12 μg 
(n=134)
LSM difference (95% CI)
Change from baseline in post-dose lung function parameters 
at Week 4
FRC,a l -0.146 -0.511 -0.366**** (-0.515, -0.216)
RV,a l -0.094 -0.559 -0.465**** (-0.649, -0.281)
ICb at rest, L -0.081 0.212 0.293**** (0.208, 0.378)
sGaw,a s-1 kPa-1 0.014 0.356 0.341**** (0.245, 0.437)
Change from baseline in pre-dose lung function parameters 
at Week 4
FeV1, L -0.051 0.159 0.209**** (0.161, 0.258)
FVC, L -0.051 0.208 0.259**** (0.182, 0.337)
RV, L -0.051 -0.195 -0.144§ (-0.292, 0.004)
sGaw, s-1 kPa-1 -0.015 0.135 0.150**** (0.095, 0.205)
Notes: ****P,0.0001 versus placebo; §P=0.0558 versus placebo. aMeasured via 
body plethysmography 2 h post-dose; bMeasured via spirometry 3 h post-dose.
Abbreviations: AB, aclidinium bromide; CI, confidence interval; FEV1, forced 
expiratory volume in 1 s; FF, formoterol fumarate; FRC, functional residual capacity; 
FVC, forced vital capacity; IC, inspiratory capacity; ITT, intent-to-treat; LSM, least 
squares mean; RV, residual volume; sGaw, specific airway conductance.
moderate-to-severe COPD (excluding trough FRC in the 
primary analysis). This improvement in lung hyperinfla-
tion was associated with improved exercise capacity and 
objectively measured physical activity and physical activity 
experience. These observations support the important role 
of lung deflation by bronchodilators in reducing hyperin-
flation-caused dyspnea during physical activity in patients 
with COPD.
The significant improvements in lung hyperinflation and 
exercise capacity observed with AB/FF versus placebo are 
comparable in magnitude with those reported in a previous 
study with aclidinium 400 μg alone,18 while the improvements 
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This numerical increase is in line with previous studies 
that have observed short-term increases in step counts 
as a consequence of BI in patients with no changes in 
pharmacotherapy.22,32,33 It was unexpected that patients receiv-
ing AB/FF had no additional improvement in physical activity 
after participating in the BI program. A potential explanation 
for the lack of further improvement in physical activity during 
BI in patients treated with AB/FF could be that the patients 
had already improved their physical activity by around 10% 
compared to baseline, which is clearly in the upper range of 
Figure 4 Change from baseline in (A) EET at Week 4 (after pharmacotherapy only) and at Week 8 (after pharmacotherapy and BI), and (B) IC during constant work rate 
cycle ergometry at Week 8 (ITT population).
Notes: aFor each individual patient, isotime was defined as the minimum EET among the constant work rate exercise tests at 75% Wmax performed on Visits 2, 3, 4, and 5. 
Data are LSMs (95% CI).
Abbreviations: AB, aclidinium bromide; BI, behavioral intervention; CI, confidence interval; EET, exercise endurance time; FF, formoterol fumarate; IC, inspiratory capacity; 
ITT, intent-to-treat; LSM, least squares mean; Wmax, peak work rate.
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Figure 5 (A) Percentage of inactive patients (,6,000 steps per day) over 8 weeks (ITT population) and (B) absolute number of steps per day over 8 weeks (ITT population).
Note: steps per day data are lsM ± se.
Abbreviations: AB, aclidinium bromide; BI, behavioral intervention; CI, confidence interval; FF, formoterol fumarate; ITT, intent-to-treat; LSM, least squares mean; OR, odds 
ratio; SE, standard error.
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improvements observed with bronchodilation in similar study 
populations and settings.18–20 Additionally, in a population 
that has already made substantial improvements in physical 
activity following effective pharmacotherapy, 4 weeks of 
BI may not have been sufficient time to foster additional 
improvements. For example, a study into effectiveness of a 
12-week semi-automated telecoaching intervention reported 
that in a patient population with an mMRC $2, patients 
increased their activity by 560 steps per day over a 3-month 
period, which is of a similar magnitude observed for the active 
treatment group in this 8-week study.22 Indeed, modifying 
behavior is a much more complex process than the provi-
sion of drug treatment for patients.34 Importantly, the initial 
increase in physical activity was not lost in patients receiving 
AB/FF when the BI was added, which is encouraging.
In addition, this study provides a new insight into the 
patient-centered concept of physical activity experience. 
Notably, patients treated with AB/FF reported less difficulty 
with physical activity, an effect not observed with BI only. 
Taken together with the improved levels of physical activity 
observed with AB/FF, the results suggest that an increase 
in physical activity due to bronchodilation does not result 
in an unpleasant, burdensome experience for patients when 
increasing their activity levels. This is potentially highly 
relevant information for health care providers trying to moti-
vate patients to adopt and maintain a more active lifestyle.
Whilst the improvements in exercise capacity and lung 
function observed in patients receiving AB/FF are in the 
range of what is considered to be clinically meaningful,30,31 
it is more challenging to appraise whether the improvements 
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in physical activity are clinically meaningful as limited data 
are available. It is known from observational studies that 
the number of steps in patients with COPD is independently 
related to hospitalizations and mortality.7,9 An interventional 
study showed that following 3 months of pulmonary rehabili-
tation, the risk of hospitalization was lower in those patients 
who had increased their daily physical activity by more than 
600 steps per day.35 Likewise, following 4 months of an 
internet-mediated, pedometer-based program, an increase of 
780 steps per day was associated with significant improve-
ments in health status in patients with COPD.32 Thus the 
combination of bronchodilation with non-pharmacological 
interventions, such as behavior modification programs to 
increase physical activity or pulmonary rehabilitation, may 
represent an important therapeutic approach to modifying 
pathophysiological characteristics and improving long-term 
outcomes in COPD.2,10,13,36
When considering the design of the ACTIVATE study 
and any impact this may have had on the results, it should 
be noted that statistical significance for the primary end 
point (trough FRC) was reached only after the use of a 
nonparametric test or after excluding four potential outliers 
(the sample size was too small to overcome random error 
in the presence of these extreme outliers). It was unexpected 
that the improvements in trough FRC did not reach statistical 
significance, given that previous evidence showed that 
aclidinium 400 μg improved trough FRC in patients with 
moderate-to-severe COPD,18 in addition to improvements 
in other lung hyperinflation end points both in patients with 
moderate-to-severe COPD18 and in patients with severe-to-
very severe COPD.37 However, when considered collectively 
with the post-dose data, this post-hoc analysis supports the 
conclusion that AB/FF significantly reduced lung hyper-
inflation. In addition to this, the 2-month study period of 
ACTIVATE is too short to show long-term treatment effects 
on physical activity, considering that it can be challenging to 
encourage long-term changes in physical activity in patients 
with COPD38 and that data for long-term improvements of 
physical activity by bronchodilators are lacking.
However, the major strength of the ACTIVATE study lies 
in the examination of the effects of multimodal intervention 
(ie, dual bronchodilation plus BI) to encourage patients to 
increase their daily physical activity levels and the assessment 
of the effects of using both an electronic activity monitor and 
PROs in the form of the D-PPAC questionnaire. Furthermore, 
by introducing BI in the second half of the ACTIVATE study 
period, it was possible to assess the effects of pharmaco-
therapy and BI alone.
In conclusion, AB/FF 400/12 μg demonstrated improve-
ments in hyperinflation, exercise tolerance, and physical 
activity versus placebo. In the short term, BI did not further 
augment the improvements observed with AB/FF.
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Supplementary materials
Inclusion and exclusion criteria
Key inclusion criteria
For inclusion in the study, patients had to fulfil all of the 
following criteria:
• Males and non-pregnant, non-lactating females 
aged $40 years.
• Patients with a clinical diagnosis of COPD according to 
Global initiative for chronic Obstructive Lung Disease 
guidelines 2014, with a post-bronchodilator forced expi-
ratory volume in 1 s (FEV
1
) $40% and ,80% of the 
predicted value and FEV
1
/forced vital capacity ,70% 
at Visit 1.
• Functional residual capacity (FRC) measured by body 
plethysmography at Visit 1 $120% of predicted value.
• Modified Medical Research Council dyspnea scale $2 
at Visit 1.
• Current or former cigarette smokers with a smoking 
history of at least 10 pack-years at Visit 1.
• Willing to participate in the telecoaching program and 
enhance their physical activity.
Key exclusion criteria
Any of the following was regarded as a criterion for exclu-
sion from the study:
• History or current diagnosis of asthma.
• Any respiratory tract infection (including upper respira-
tory tract) or COPD exacerbation in the 6 weeks prior to 
Visit 1 or during the run-in period.
• Hospitalization for an acute COPD exacerbation within 
3 months prior to Visit 1 or during the run-in period.
• Clinically significant respiratory conditions other than 
COPD.
• Use of long-term oxygen therapy ($15 h/day).
• Oxygen saturation #85% during exercise testing at 
Visit 1, 2, or 3 prior to randomization.
• Body Mass Index $40 kg/m2.
• Pulmonary rehabilitation during the study and/or within 
3 months prior to Visit 1 or during the run-in period.
• Clinically significant cardiovascular conditions.
• Clinically relevant abnormalities in the results of blood 
pressure, electrocardiogram, or physical examination at 
Visit 1.
• Conditions other than COPD that may have contributed 
to dyspnea and exercise limitation or with contraindica-
tions to clinical exercise testing according to American 
Thoracic Society recommendations for Cardiopulmonary 
Exercise Testing.
• Patients who cycled ,2 minutes or .15 minutes during 
the constant work rate exercise tests conducted at Visit 
2 (run-in visit) or at Visit 3 even after adjustment of the 
work load.
Patients who had participated in previous trials involving 
aclidinium bromide (AB) monotherapy or AB/formoterol 
fumarate (FF) were allowed to be included in the study.
Details of statistical analyses
Assuming a screening failure rate of 25% and a drop-out 
rate of 10%, 335 patients were required to be screened to 
ensure 267 were randomized and 240 patients completed 
the study. Change from baseline in trough FRC and FEV
1
 
at Week 4 of treatment was analyzed using analysis of 
covariance (ANCOVA) models, adjusted for age and baseline 
values as covariates, with treatment group, sex, and smoking 
status as fixed-effect factors. To explore the robustness of 
the ANCOVA model, a nonparametric Wilcoxon–Mann–
Whitney test and the estimated asymptotic shift Hodges–
Lehmann test were carried out once the trial was unblinded. 
In addition, an analysis of potential outliers and influential 
data was carried out through the interquartile range, studen-
tized residuals, and Cook’s distance. Change from baseline 
in inspiratory capacity, exercise endurance time, physical 
activity, and Daily PROactive Physical Activity in COPD 
questionnaire score at Weeks 4 and 8 were analyzed using 
a mixed model for repeated measures (MMRM), adjusted 
for age and baseline values as covariates with treatment 
group, sex, smoking status, visit, and treatment-by-visit 
interaction as fixed-effect factors. Percentage of inactive 
patients data and the effect of behavioral intervention were 
analyzed using a logistic random-effect model for repeated 
measures for inactive patients, with a cut-off of ,6,000 steps 
per day, using the same adjustments and covariates as the 
MMRM analyses.
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AB/FF improves hyperinflation and physical activity in COPD
Table S1 IeCs/IrBs consulted
Name and address of IEC/IRB
Canada
Hamilton Integrated Research Ethics Board, 293 Wellington Street North Suite 102, Hamilton, ON, Canada, L8L 8E7
Queen’s University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board, Queen’s University, Kingston, ON, Canada, K7L 3N6
Comité d’éthique de la recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), 2725, Chemin Ste-Foy Québec, 
QC, Canada, G1V 4G5
University of Saskatchewan Biomedical Research Ethics Board, University of Saskatchewan Box 5000 RPO University 1607-110 Gymnasium Place 
Saskatoon, SK, Canada, S7N 4J8
Germany
Central and Local Ethics Committee: Ethikkommission der Ärztekammer Schleswig-Holstein Bismarckallee 8–12, 23795 Bad Segeberg
Local Ethics Committee: Ethikkommission der Landesärztekammer Hessen Im Vogelsgesang 3, 60488 Frankfurt am Main
Local Ethics Committee: Ethikkommission der Ärztekammer Westfalen-Lippe und der Medizinischen, Fakultät der WWU Münster Gartenstr. 
210–214, 48147 Münster
Local Ethics Committee: Ethikkommission der Ärztekammer Hamburg Weidestr. 122 b, 22083 Hamburg
Local Ethics Committee: Ethikkommission der Ärztekammer Nordrhein Tersteegenstraße 9, 40474 Düsseldorf
Local Ethics Committee: Ethikkommission der Friedrich-Schiller-Universität Jena Bachstraße 18, 07740 Jena
Local Ethics Committee: Ethikkommission der Bayerischen Landesärztekammer Mühlbaurstraße 16, 81677 München
Local Ethics Committee: Ethikkommission zur Beurteilung medizinischer Forschung am Menschen der Ärztekammer Niedersachsen Berliner Allee 20, 
30175 hannover
Local Ethics Committee: Ethikkommission der Albert-Ludwigs-Universität Freiburg Engelberger Str. 21, 79106 Freiburg
Local Ethics Committee: Ethikkommission des Landes Berlin, Landesamt für Gesundheit und Soziales Fehrbelliner Platz 1, 10707 Berlin
Hungary
Medical Research Council Ethics Committee for Clinical Pharmacology, H-1051 Budapest, Arany János, u. 6–8., Hungary
Spain
Central and Local Ethics Committee: Comité Ético de Investigación Clínica del Hospital Clínico U. de Valencia, Fundación INCLIVA c/ Menéndez 
Pelayo, 4 46010 Valencia, Spain
Local Ethics Committee: Comité Ético de Investigación Clínica de Cáceres, Secretaría del CEIC de Cáceres Hospital Ntra. Sra. de la Montaña – Avda. 
de España, 2 10004 Cáceres, Spain
Local Ethics Committee: Comité Ético de Investigación Clínica del Instituto de Ciencias Médicas, Secretaría del CEIC – Instituto de Ciencias Médicas, 
C/ Poeta Quintana, 56 03004 Alicante, Spain
Local Ethics Committee: Comité Ético de Investigación Clínica del Hospital U. La Paz, Secretaría Técnica del CEIC – Hospital Universitario La Paz 
Planta 8ª Hospital General – Paseo de la Castellana, 261 28046 Madrid, Spain
Abbreviations: IEC, independent ethics committee; IRB, institutional review board.
Figure S1 Change from baseline in daily duration of at least moderate activitiesa at Week 4 (ITT population).
Notes: Data are LSMs (95% CI). aModerate activities are those with an intensity $3.0 MeTs.
Abbreviations: AB, aclidinium bromide; CI, confidence interval; FF, formoterol fumarate; ITT, intent-to-treat; LSM, least squares mean; MET, metabolic equivalents.
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journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
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Figure S2 Change from baseline in activity-related energy expenditure at Week 4 (ITT population).
Note: Data are LSMs (95% CI).
Abbreviations: AB, aclidinium bromide; CI, confidence interval; FF, formoterol fumarate; ITT, intent-to-treat; LSM, least squares mean.
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